News | March 16, 2026
C2N Diagnostics expands Alzheimer’s blood test to South Korea via BeauBrain partnership
Under the agreement, healthcare professionals in the country will gain access to C2N’s PrecivityAD2 blood test
Under the agreement, healthcare professionals in the country will gain access to C2N’s PrecivityAD2 blood test
This study demonstrates the power of real-time glucose information for people with Type 2 diabetes treated with basal insulin
The expanded ownership is expected to improve access to Cialis for millions of men in Asia affected by ED and BPH
There are limited treatment options available for patients living with non-diabetic CKD, and the unmet need is high for new treatments to delay kidney disease progression and reduce cardiovascular risk
Cadila Pharmaceuticals’ journey has been marked by several milestones, including the development of indigenous formulations, expansion into global markets, and the creation of robust manufacturing and R&D capabilities
The facility will manufacture the critical antibiotic intermediate Amino Cephalosporanic Acid (ACA), a key component in the production of cephalosporin antibiotics
The product is bioequivalent and therapeutically equivalent to Fresenius Kabi’s reference drug (NDA 212832)
Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk
Subscribe To Our Newsletter & Stay Updated
